Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles

Virology

Volumn 361, Issue 2, 2007, Pages 435-446

  Culp, Timothy D ^a   Spatz, Christin M ^a   Reed, Cynthia A ^a   Christensen, Neil D ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Fab fragments; HPV 11; HPV 16; Human papillomavirus; Monoclonal antibodies; Pseudovirus; Single chain variable fragments (scFv); Vaccine; Viral epitopes; Virus like particles (VLPs); Virus neutralization

Indexed keywords

CAPSID PROTEIN; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; L 1 EPITOPE; MONOCLONAL ANTIBODY; RECOMBINANT VACCINE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CALCULATION; CONFORMATION; CROSS LINKING; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; VIRION; VIRUS CAPSID; VIRUS INFECTION; VIRUS NEUTRALIZATION; VIRUS TYPING; WART VIRUS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CAPSID; CAPSID PROTEINS; CELL LINE, TUMOR; EPITOPES; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; NEUTRALIZATION TESTS; ONCOGENE PROTEINS, VIRAL;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MIRIDAE;

EID: 34147170611     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.12.002     Document Type: Article

References (46)

1. Billich A. HPV vaccine MedImmune/GlaxoSmithKline. Curr. Opin. Investig. Drugs 4 (2003) 210-213
2. Booy F.P., Roden R.B., Greenstone H.L., Schiller J.T., and Trus B.L. Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 A resolution. J. Mol. Biol. 281 (1998) 95-106
3. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., Schiller J.T., and Lowy D.R. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69 (1995) 3959-3963
4. Buck C.B., Pastrana D.V., Lowy D.R., and Schiller J.T. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78 (2004) 751-757
5. Carter J.J., Wipf G.C., Benki S.F., Christensen N.D., and Galloway D.A. Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J. Virol. 77 (2003) 11625-11632
6. Carter J.J., Wipf G.C., Madeleine M.M., Schwartz S.M., Koutsky L.A., and Galloway D.A. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J. Virol. 80 (2006) 4664-4672
7. Chen X.S., Garcea R.L., Goldberg I., Casini G., and Harrison S.C. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol. Cell 5 (2000) 557-567
8. Christensen N.D., Kreider J.W., Cladel N.M., Patrick S.D., and Welsh P.A. Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J. Virol. 64 (1990) 5678-5681
9. Christensen N.D., Höpfl R., DiAngelo S.L., Cladel N.M., Patrick S.D., Welsh P.A., Budgeon L.R., Reed C.A., and Kreider J.W. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J. Gen. Virol. 75 (1994) 2271-2276
10. Christensen N.D., Kirnbauer R., Schiller J.T., Ghim S.-J., Schlegel R., and Kreider J.W. Human papillomavirus types 6 and 11 have antigenically distinct strongly-immunogenic conformationally-dependent neutralizing epitopes. Virology 205 (1994) 329-335
11. Christensen N.D., Dillner J., Eklund C., Carter J.J., Wipf G.C., Reed C.A., Cladel N.M., and Galloway D.A. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223 (1996) 174-184
12. Christensen N.D., Reed C.A., Cladel N.M., Hall K., and Leiserowitz G.S. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 224 (1996) 477-486
13. Christensen N.D., Reed C.A., Cladel N.M., Han R., and Kreider J.W. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J. Virol. 70 (1996) 960-965
14. Christensen N.D., Cladel N.M., Reed C.A., Budgeon L.R., Embers M.E., Skulsky D.M., McClements W.L., Ludmerer S.W., and Jansen K.U. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 291 (2002) 324-334
15. Cleveland S.M., Buratti E., Jones T.D., North P., Baralle F., McLain L., McInerney T., Durrani Z., and Dimmock N.J. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response. Virology 266 (2000) 66-78
16. Combita A.L., Touze A., Bousarghin L., Christensen N.D., and Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J. Virol. 76 (2002) 6480-6486
17. Culp T.D., and Christensen N.D. Quantitative RT-PCR assay for HPV infection in cultured cells. J. Virol. Methods 111 (2003) 135-144
18. Culp T.D., Budgeon L.R., and Christensen N.D. Human papillomaviruses bind a basal extracellular matrix component secreted by keratinocytes which is distinct from a membrane-associated receptor. Virology 347 (2006) 147-159
19. Culp T.D., Budgeon L.R., Marinkovich M.P., Meneguzzi G., and Christensen N.D. Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells. J. Virol. 80 (2006) 8940-8950
20. Dillner J., Dillner L., Utter G., Eklund C., Rotola A., Costa S., and DiLuca D. Mapping of linear epitopes of human papillomavirus type 16: the L1 and L2 open reading frames. Int. J. Cancer 45 (1990) 529-535
21. Edwards M.J., and Dimmock N.J. Two influenza A virus-specific Fabs neutralize by inhibiting virus attachment to target cells, while neutralization by their IgGs is complex and occurs simultaneously through fusion inhibition and attachment inhibition. Virology 278 (2000) 423-435
22. Edwards M.J., and Dimmock N.J. A haemagglutinin (HA1)-specific FAb neutralizes influenza A virus by inhibiting fusion activity. J. Gen. Virol. 82 (2001) 1387-1395
23. Fligge C., Schäfer F., Selinka H.C., Sapp C., and Sapp M. DNA-induced structural changes in the papillomavirus capsid. Virology 75 (2001) 7727-7731
24. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., Zahaf T., Innis B., Naud P., De Carvalho N.S., Roteli-Martins C.M., Teixeira J., Blatter M.M., Korn A.P., Quint W., and Dubin G. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
25. Kirnbauer R., Chandrachud L.M., O'Neil B.W., Wagner E.R., Grindlay G.J., Armstrong A., McGarvie G.M., Schiller J.T., Lowy D.R., and Campo M.S. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219 (1996) 37-44
26. Klasse P.J., and Sattentau Q.J. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J. Gen. Virol. 83 (2002) 2091-2108
27. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., Chiacchierini L.M., and Jansen K.U. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347 (2002) 1645-1651
28. Kreider J.W., Howett M.K., Leure-Dupree A.E., Zaino R.J., and Weber J.A. Laboratory production in vivo of infectious human papillomavirus type 11. J. Virol. 61 (1987) 590-593
29. Ludmerer S.W., Benincasa D., and Mark III G.E. Two amino acid residues confer type-specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. J. Virol. 70 (1996) 4791-4794
30. Ludmerer S.W., Benincasa D., Mark I.G.E., and Christensen N.D. A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear surface-exposed epitope. J. Virol. 71 (1997) 3834-3839
31. Ludmerer S.W., McClements W.L., Wang X.M., Ling J.C., Jansen K.U., and Christensen N.D. HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain. Virology 266 (2000) 237-245
32. McInerney T.L., McLain L., Armstrong S.J., and Dimmock N.J. A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event. Virology 233 (1997) 313-326
33. Moore J.P., Cao Y., Qing L., Sattentau Q.J., Pyati J., Koduri R., Robinson J., Barbas III C.F., Burton D.R., and Ho D.D. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69 (1995) 101-109
34. Munoz N., Bosch F.X., Castellsague X., Diaz M., De Sanjose S., Hammouda D., Shah K.V., and Meijer C.J. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 111 (2004) 278-285
35. Olcese V.A., Chen Y., Schlegel R., and Yuan H. Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitope. BMC Microbiol. 4 (2004) 29
36. Pastrana D.V., Buck C.B., Pang Y.Y., Thompson C.D., Castle P.E., FitzGerald P.C., Kruger K.S., Lowy D.R., and Schiller J.T. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321 (2004) 205-216
37. Roden R.B.S., Greenstone H.L., Kirnbauer R., Booy F.P., Jessie J., Lowy D.R., and Schiller J.T. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J. Virol. 70 (1996) 5875-5883
38. Roden R.B.S., Armstrong A., Haderer P., Christensen N.D., Hubbert N.L., Lowy D.R., Schiller J.T., and Kirnbauer R. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J. Virol. 71 (1997) 6247-6252
39. Sadeyen J.R., Tourne S., Shkreli M., Sizaret P.Y., and Coursaget P. Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope. Virology 309 (2003) 32-40
40. Schofield D.J., Stephenson J.R., and Dimmock N.J. Variations in the neutralizing and haemagglutination-inhibiting activities of five influenza A virus-specific IgGs and their antibody fragments. J. Gen. Virol. 78 Pt. 10 (1997) 2431-2439
41. Slupetzky K., Shafti-Keramat S., Lenz P., Brandt S., Grassauer A., Sara M., and Kirnbauer R. Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops. J. Gen. Virol. 82 (2001) 2799-2804
42. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., Newsome J.A., Jenson A.B., and Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 11553-11557
43. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., Wheeler C.M., Koutsky L.A., Malm C., Lehtinen M., Skjeldestad F.E., Olsson S.E., Steinwall M., Brown D.R., Kurman R.J., Ronnett B.M., Stoler M.H., Ferenczy A., Harper D.M., Tamms G.M., Yu J., Lupinacci L., Railkar R., Taddeo F.J., Jansen K.U., Esser M.T., Sings H.L., Saah A.J., and Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6 (2005) 271-278
44. Wang Z.H., Christensen N., Schiller J.T., and Dillner J. A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J. Gen. Virol. 78 (1997) 2209-2215
45. White W.I., Wilson S.D., Palmer-Hill F.J., Woods R.M., Ghim S.J., Hewitt L.A., Goldman D.M., Burke S.J., Jenson A.B., Koenig S., and Suzich J.A. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J. Virol. 73 (1999) 4882-4889
46. Yuan W., and Parrish C.R. Comparison of two single-chain antibodies that neutralize canine parvovirus: analysis of an antibody-combining site and mechanisms of neutralization. Virology 269 (2000) 471-480